Treatment of quiescent Swiss 3T3 fibroblasts with serum, or with the phosphatase inhibitors okadaic acid and vanadate, induced a 2-to 11-fold activation of the serine/ threonine RAC protein kinase (RAC-PK). Kinase activation was accompanied by decreased mobility of RAC-PK on SDS/ PAGE such that three electrophoretic species (a to c) of the kinase were detected by immunoblot analysis, indicative of differentially phosphorylated forms. Addition of vanadate to arrested cells increased the RAC-PK phosphorylation level 3-to 4-fold. Unstimulated RAC-PK was phosphorylated predominantly on serine, whereas the activated kinase was phosphorylated on both serine and threonine residues. Treatment of RAC-PK in vitro with protein phosphatase 2A led to kinase inactivation and an increase in electrophoretic mobility. Deletion of the N-terminal region containing the pleckstrin homology domain did not affect RAC-PK activation by okadaic acid, but it reduced vanadate-stimulated activity and also blocked the serum-induced activation. Deletion of the serine/ threonine rich C-terminal region impaired both RAC-PKa basal and vanadate-stimulated activity. Studies using a kinase-deficient mutant indicated that autophosphorylation is not involved in RAC-PKa activation. Stimulation of RAC-PK activity and electrophoretic mobility changes induced by serum were sensitive to wortmannin. Taken together the results suggest that RAC-PK is a component of a signaling pathway regulated by phosphatidylinositol (PI) 3-kinase, whose action is required for RAC-PK activation by phosphorylation.
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The RAC-PKs (for related to PKA and C protein kinases; also known as PKB/Akt) represent a subfamily of second messenger-regulated serine/threonine protein kinases (1) . Two human genes have been identified, termed RACa and -Pf that are 90% homologous (2) (3) (4) . Both genes appear to be widely expressed in human tissues, implying that they play an important role in cell signaling. Mouse RACa (c-akt) is the cellular homologue of the viral oncogene v-akt, generated by fusion of the Gag protein from the AKT8 retrovirus to the N terminus of mouse RAC-PKa, giving rise to a 105-kDa phosphoprotein that is myristilated at its N terminus (5, 6) . The mouse protein is mainly cytosolic (90%), whereas the oncoprotein is apparently equally distributed between the plasma membrane, nucleus, and cytoplasm (6) . Human RACf3 was found to be amplified in 10% of human ovarian carcinomas (4) , suggesting the involvement of the RAC-PK subfamily members in regulation of cell growth. The Drosophila homologue (DRAC) shows 75% homology to the human isoforms and is ubiquitously expressed throughout the Drosophila life cycle (7, 8) .
All characterized members of the RAC-PK subfamily have a similar domain structure: an N-terminal pleckstrin homology
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(PH) domain, a centrally located catalytic domain, and a serine/threonine rich C-terminal region (7) . The catalytic domain exhibits a high degree of similarity to those of both protein kinase C and protein kinase A, 75% and 65%, respectively (3, 7) . Furthermore, RAC-PKs possess a PH domain (9, 10) that is "70% similar between mammals, Drosophila and Caenorhabditis elegans (7) . PH domains have been identified in more than 90 signaling and cytoskeletal molecules, many of which associate with membranes (11) . The C-terminal region is rich in serine and threonine residues that are conserved between Drosophila and human RAC-PK (3, 7) and therefore represents a potential site of kinase regulation by phosphorylation.
We have shown previously that RAC-PK activity from Drosophila is developmentally regulated, being '8-fold higher in adult flies than in early embryos (7) , and have proposed that phosphorylation may be a possible regulatory mechanism of DRAC-PK activity. Here we demonstrate that RAC-PK activity from mammalian cell lines is stimulated by serum and phosphatase inhibitors, and that reversible phosphorylation is a key mechanism of its regulation. The PH domain is required for RAC-PK activation, but is not a target for the activating phosphorylation.
MATERIALS AND METHODS
Construction of Expression Vectors. Hemagglutinin (HA) epitope-tagged constructs (HA-RAC-PKa and HA-ANRACPKa) were prepared by ligating an HA epitope encoding oligonucleotide to the RAC-PKa (2) and ANRAC-PKa (lacking the N-terminal 117 amino acids) cDNAs in-frame with the initiator methionine, in the mammalian expression vector pECE (12) . The HA-RAC-PKaAC and HA-ANRAC-PKaAC constructs (lacking N-terminal 117 and/or C-terminal 59 amino acids, respectively) were prepared by truncation at Leu421 using a CelII restriction site. Kinase-deficient HA-RAC-PKaK179A was created by the two-stage PCR technique. All constructs were confirmed by restriction analysis, sequencing, and expression in COS-1 cells.
Cell Culture. Quiescent Swiss 3T3 cells (13) and transfected COS-1 cells (7) were serum-starved for 24 hr, followed by stimulation with 10% fetal calf serum (FCS), 1 ,uM okadaic acid, or 0.1 mM vanadate prepared with 0.2 mM H202 (14) . Pretreatment of quiescent Swiss 3T3 cells with 200 nM wortmannin and 5 nM rapamycin before serum stimulation was carried out as described (15 recognize the f isoform, as its C-terminus differs from that of RAC-PKa only in the last three amino acids (4) . HA-tagged versions of RAC-PKa were immunoprecipitated using the 12CA5 monoclonal antibody. Immune complexes were collected using protein A-Sepharose beads. RAC-PK activity was assayed as described with myelin basic protein as substrate (2) .
Immunoprecipitation and assay of p70s6k were as reported (15 (Fig. 4C) . Synergism between okadaic acid and serum was also observed in this system (data not shown). The activation of HA-RAC-PKa by okadaic acid and vanadate was followed by a decrease in the SDS/PAGE mobility (Fig. 4B, lanes 1-3) . Deletion of the N-terminal PH domain did not affect basal activity of the kinase, but it reduced vanadate-stimulated activity by '70%, and almost completely blocked serum-induced activation, without affecting its electrophoretic mobility (Fig. 4 B and C) .
In contrast, okadaic acid stimulation led to an efficient activation and concomitant electrophoretic mobility changes of HA-ANRAC-PKa (Fig. 4 B and C (15 min (Fig. 4D, top  panel) . Following vanadate treatment, both active and inactive proteins displayed decreased electrophoretic mobility (Fig.  4D, bottom panel) . In contrast with the earlier experiments with the endogenous enzyme from Swiss 3T3 cells (see Fig. 2) , it was not possible to observe a large increase in the phosphorylation of the overexpressed protein (Fig. 4D, top panel (Fig. 5A) . On the other hand, rapamycin pretreatment did not exert any significant effect on RAC-PK activation (Fig. 5A ). In the same experiment, both wortmannin and rapamycin pretreatment abolished a 3-fold p70s6k activation (Fig. 5A) . Interestingly, wortmannin also reduced RAC-PK activation by vanadate (30-40%) and prevented the emergence of the slowest migrating form on SDS/PAGE (data not shown). Wortmannin, but not rapamycin, also blocked insulin-induced activation of HA-RAC-PKa overexpressed in 293 cells (data not shown). These results suggest that RAC-PK activation by serum, insulin, and at least partially by vanadate is dependent on PI 3-kinase activity.
DISCUSSION
The data presented here demonstrate that RAC-PK activity is regulated by reversible phosphorylation. We between the active and less active state (see Fig. 6 ). The data obtained by in vitro phosphatase treatment are consistent with PP2A being a primary negative regulator of RAC-PK activity.
Analysis of the role of the PH domain in RAC-PK activation by growth factor receptors indicates that it probably functions as an adaptor. In contrast, Kohn et al. (22) reported that the PH domain is not required for RAC-PK activation by insulin in Chinese hamster ovary cells overexpressing insulin receptors. These data are reminiscent of the insulin receptor substrate-1 whose PH domain is required for signaling from the endogenous receptor, but the defect is overcome by insulin receptor overexpression (23) .
It was reported that RAC-PK molecules dimerize through the PH domain (24) , and that the PH domain is required for RAC-PK activation by platelet-derived growth factor (20, 24) . This led to a model (25) in which RAC-PK dimers are activated by autophosphorylation following elevation of 3-phosphorylated phosphoinositides produced by PI 3-kinase. However, our studies with the overexpressed wild-type and kinasedeficient RAC-PKa showed that the kinase is extensively autophosphorylated in vivo in serum-starved cells, but only has basal activity. We conclude that the phosphorylation responsible for the activation occurs through the action of another, upstream kinase, based on several lines of evidence: (i) both wild-type and kinase-deficient RAC-PKa undergo similar electrophoretic mobility changes following vanadate stimulation, (ii) only a limited amount of overexpressed RAC-PKa is activated following stimulation of cell, (iii) the increase in RAC-PK activity and (activating) phosphorylation induced by serum and vanadate are sensitive to wortmannin implying that they occur through a PI 3-kinase dependent mechanism, whereas basal activity and phosphorylation are unaffected by this drug. This is supported by data from Burgering and Coffer (21) showing that wortmannin pretreatment blocked the appearance of platelet-derived growth factor-induced RAC-PK phosphorylation, without affecting its basal phosphorylation.
In this context the role of the PH domain, which binds PI 3-kinase generated phospholipids, would be to ensure RAC-PK translocation or attachment to the membranes. The structure of the PH domain of phospholipase C-1 81 bound to inositol (1, 4, 5) -trisphosphate revealed that residues involved in the high-affinity interactions are conserved among different PH domains. This suggests that phosphoinositides binding through electrostatic interactions may be a common mecha-nism for providing membrane localization of many PH domain containing proteins (26) . In our model it is necessary to speculate that the activating kinase is also located at the membrane and regulated by phospholipids. PI 3-kinase itself is also a possible candidate for the RAC-PK kinase, as it has been demonstrated that lipid kinases may function as protein kinases (27) .
Identification of the phosphorylation sites associated with RAC-PK regulation is of considerable importance for a detailed understanding of the activating mechanism and delineation of the signaling pathway. The available data indicate that these sites reside in the catalytic domain and/or Cterminal region. Based on comparison with the structures of protein kinase A, CDK2, and p42maPk (28) , Thr308 of RACPKa can be predicted as a potential phosphorylation site involved in the regulation of its kinase activity. Furthermore, the C-terminal domain of RAC-PK contains two conserved motifs that were shown to be involved in the regulation of other kinases by phosphorylation. First, Thr450 in RAC-PKa corresponds to a similar site (TPXD) in PKCP1 involved in maturation and activation of the enzyme (29) . Second, the sequence context of Ser473 in RAC-PKa is homologous to the principal rapamycin-sensitive phosphorylation site in p70s6k (30) . Significantly, all of these sites are conserved in the 3-isoform and in DRAC-PK (7) .
The only downstream target of RAC-PK identified thus far is glycogen synthase kinase-3, which can be phosphorylated and inactivated by RAC-PK following insulin stimulation (18 
